Research progress of proprotein convertase subtilisin/kexin type 9 in myocardial infarction and ische-mia reperfusion / 心血管康复医学杂志

ABSTRACT

At present,proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor has been widely used in clinical field as a fast and effective drug to reduce low density lipoprotein cholesterol(LDL-C),in addition to regulating LDL-C to affect the process of atherosclerosis.Clinical data show that PCSK9 is upregulated in ischemic heart,and downregulation of PCSK9 expression can benefit infarct size,post-infarct inflammation and remodeling,and cardiac dysfunction after ische-mia/reperfusion.In subjects with increased cardiovascular risk,PCSK9 inhibition was associated with reduced incidence rates of myocardial infarction,stroke,and coronary revascularization,as well as improved endothelial function.This article reviews the role of PCSK9 in myocardial infarction and ischemia-reperfusion after myocardial infarction.